Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our Dark Pool Levels

CABA
Cabaletta Bio, Inc. Common Stock
stock NASDAQ

At Close
Jul 31, 2026 3:59:56 PM EDT
2.69USD-1.103%(-0.03)1,907,714
0.00Bid   0.00Ask   0.00Spread
Pre-market
Jul 31, 2026 8:56:30 AM EDT
2.75USD+1.040%(+0.03)200
After-hours
Jul 31, 2026 4:38:30 PM EDT
2.68USD-0.204%(-0.01)221,463
OverviewOption ChainMax PainOptionsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Jan 11, 2022
08:00AM EST  Cabaletta Bio Strengthens Executive Leadership Team with   GlobeNewswire Inc
Jan 10, 2022
08:00AM EST  Cabaletta Bio to Present at the 40th Annual J.P. Morgan Healthcare   GlobeNewswire Inc
Jan 3, 2022
08:00AM EST  Cabaletta Bio to Present at the H.C. Wainwright BioConnect Conference   GlobeNewswire Inc
Dec 15, 2021
08:56AM EST  Morgan Stanley Maintains Overweight on Cabaletta Bio, Lowers Price Target to $15   Benzinga
Dec 14, 2021
02:39PM EST  Mid-Afternoon Market Update: Dow Falls 100 Points; Terminix Shares Spike Higher   Benzinga
12:40PM EST  Mid-Day Market Update: Nasdaq Tumbles 200 Points; MIND Technology Shares Jump   Benzinga
10:46AM EST  Shares of Cabaletta Bio, Inc. (CABA) tanked over 65% on Tuesday morning after the company reported top-line biologic activity data from two lowest dose cohorts in DesCAARTes trial in patients with mucosal pemphigus vulgaris.   RTTNews
10:13AM EST  Mid-Morning Market Update: Markets Mostly Lower; Producer Prices Rise 0.8% In November   Benzinga
10:12AM EST  Mid-Morning Market Update: Markets; Producer Prices Rise 0.8% In November   Benzinga
07:06AM EST  Cabaletta Bio Reports Top-line Biologic Activity Data From Two Lowest Dose Cohorts In DesCAARTes Trial In Patients With Mucosal Pemphigus Vulgaris   Benzinga
07:00AM EST  Cabaletta Bio Reports Top-line Biologic Activity Data from Two   GlobeNewswire Inc
Dec 8, 2021
10:04AM EST  Benzinga's Top Ratings Upgrades, Downgrades For December 8, 2021   Benzinga
07:26AM EST  Wells Fargo Initiates Coverage On Cabaletta Bio with Overweight Rating, Announces Price Target of $17   Benzinga
Nov 9, 2021
08:00AM EST  Cabaletta Bio Expands Executive Leadership Team with Appointments   GlobeNewswire Inc
Nov 2, 2021
10:37AM EDT  Cabaletta Posts Cell Therapy Data From Third Cohort Of Autoimmune Skin Disorder Trial   Benzinga
Nov 1, 2021
07:13AM EDT  Cabaletta Bio Q3 EPS $(0.45) Beats $(0.50) Estimate   Benzinga
07:05AM EDT  Dose dependent increase in DSG3-CAART persistence observed in the third dose cohort with 500 million DSG3-CAART cells relative to the first two low dose cohorts in DesCAARTes Phase 1 clinical trial throughout the 28 days following infusion   GlobeNewswire Inc
07:03AM EDT  Cabaletta Bio Reports Clinical Data From 3rd Dose Cohort In DesCAARTes Trial In Patients With mPV   Benzinga
07:00AM EDT  Dose dependent increase in DSG3-CAART persistence observed in the third dose cohort relative to the first two low dose cohorts throughout the 28 days following infusion   GlobeNewswire Inc
Oct 15, 2021
04:31PM EDT  Cabaletta Bio Announces Presentation Of Preclinical Data Supporting PLA2R-CAART As Potential Precision Therapy For Antigen-Specific B Cell Depletion An PLA2R Membranous Nephropathy At ASN Kidney Week 2021   Benzinga
04:30PM EDT  Chimeric AutoAntibody Receptor (CAAR) T cells specifically recognized and eliminated anti-PLA2R antibody-expressing B cells in vitro   GlobeNewswire Inc
Sep 28, 2021
08:00AM EDT  Cabaletta Bio to Present at the Chardan 5th Annual Genetic   GlobeNewswire Inc
Sep 7, 2021
08:00AM EDT  Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, today announced that Michael Gerard has been appointed general counsel.   GlobeNewswire Inc
Sep 2, 2021
08:00AM EDT  Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, today announced that the Company will participate in two upcoming investor conferences in September:   GlobeNewswire Inc
Aug 18, 2021
08:57AM EDT  Cabaletta Bio's Cell Therapy Shows Encouraging Safety Profile In Autoimmune Skin Disorder   Benzinga
07:38AM EDT  The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline   Benzinga
07:01AM EDT  Cabaletta Bio Reports Clinical Data From Second Dose Cohort In DesCAARTes Trial In Patients With mPV   Benzinga
07:00AM EDT  No dose-limiting toxicities (DLTs) or clinically relevant adverse events observed as of August 17 using 100 million cells in the second dose cohort   GlobeNewswire Inc
Aug 5, 2021
08:08AM EDT  The Daily Biotech Pulse: Merck Reports Positive Keytruda Readout, Moderna Slips Despite Q2 Beat, Bayer To Buy Vividion For Up To $2B, GlycoMimetics Gets New CEO   Benzinga
07:52AM EDT  Cabaletta Bio Q2 EPS $(0.45) Down From $(0.35) YoY   Benzinga
07:30AM EDT  Company continues to make progress on the DesCAARTes trial for DSG3-CAART; expects to report second and third cohort safety data in 3Q21 and 4Q21, respectively, and data on target engagement 3 to 6 months after each completed cohort   GlobeNewswire Inc
Jun 30, 2021
10:56AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For June 30, 2021   Benzinga
05:06AM EDT  Mizuho Initiates Coverage On Cabaletta Bio with Buy Rating, Announces Price Target of $22   Benzinga
Jun 28, 2021
08:00AM EDT  Dr. Bruns early and late-stage clinical development expertise in autoimmune, neurologic, and renal disease areas aligns well with Cabalettas rapidly emerging pipeline   GlobeNewswire Inc
Jun 22, 2021
08:12AM EDT  The Daily Biotech Pulse: Sanofi, Translate Bio Start Early Stage Seasonal Flu Vaccine Study, Dr. Reddy's Launches Generic Vascepa, Halozyme Strikes Licensing Deal   Benzinga
May 27, 2021
08:00AM EDT  Cabaletta Bio to Present at the Jefferies Healthcare Conference   GlobeNewswire Inc
May 3, 2021
01:18PM EDT  Cabaletta Bio's Cell Therapy In Skin Blistering Disorder Shows Favorable Safety Profile   Benzinga
07:16AM EDT  Cabaletta Bio Q1 EPS $(0.41) Down From $(0.33) YoY   Benzinga
07:05AM EDT  Acute safety data from the first cohort in the DesCAARTes trial announced today; no dose limiting toxicities (DLTs) or clinically relevant adverse events observed in the first dose cohort as of April 30, 2021   GlobeNewswire Inc
07:02AM EDT  Cabaletta Bio Reports Acute Safety Data From First Dose Cohort In DesCAARTes Trial; Says No Dose Limiting Toxicities Or Clinically Relevant Adverse Events Observed As Of Apr. 30   Benzinga
07:00AM EDT  No dose limiting toxicities (DLTs) or clinically relevant adverse events observed in the first dose cohort as of April 30, 2021   GlobeNewswire Inc
Apr 7, 2021
08:00AM EDT  Cabaletta Bio to Present at the 20th Annual Needham Healthcare   GlobeNewswire Inc
Mar 17, 2021
06:38AM EDT  HC Wainwright & Co. Maintains Buy on Cabaletta Bio, Raises Price Target to $22   Benzinga
Mar 16, 2021
07:32AM EDT  Cabaletta Bio Q4 EPS $(0.40) Down From $(0.33) YoY   Benzinga
07:30AM EDT  Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, today announced financial results for the fourth quarter and full year ended December 31, 2020.   GlobeNewswire Inc
Jan 8, 2021
10:04AM EST  Benzinga's Top Upgrades, Downgrades For January 8, 2021   Benzinga
04:55AM EST  Chardan Capital Initiates Coverage On Cabaletta Bio with Buy Rating, Announces Price Target of $21   Benzinga
Jan 7, 2021
08:00AM EST  Cabaletta Bio to Present at the 39th Annual J.P. Morgan Healthcare   GlobeNewswire Inc
Jan 4, 2021
08:00AM EST  Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, today announced that Steven Nichtberger, M.D., President and Chief Executive Officer, will participate in two upcoming investor conferences in January:   GlobeNewswire Inc
Dec 8, 2020
04:31PM EST  Cabaletta Bio Announces First Patient Dosed In DesCAARTes Trial Of DSG3-CAART For Treatment Of Mucosal-Dominant Pemphigus Vulgaris   Benzinga
04:30PM EST  First patient ever infused with a CAAR (chimeric autoantibody receptor) T cell therapy product candidate expands the potential clinical application of CAR T technology beyond cancer into autoimmune diseases   GlobeNewswire Inc
Nov 23, 2020
08:00AM EST  Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, today announced that Steven Nichtberger, M.D., President and Chief Executive Officer, will participate in two upcoming investor conferences in December:   GlobeNewswire Inc
Nov 10, 2020
05:17PM EST  Cabaletta Bio Inc Files For Mixed Shelf Offering Of Up To $250M   Benzinga
07:34AM EST  Cabaletta Bio Q3 EPS $(0.36) Up From $(2.17) YoY   Benzinga
07:30AM EST  Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, today announced financial results for the third quarter ended September 30, 2020 and provided a business update.   GlobeNewswire Inc
Oct 13, 2020
06:59AM EDT  HC Wainwright & Co. Initiates Coverage On Cabaletta Bio with Buy Rating, Announces Price Target of $20   Benzinga
Sep 25, 2020
08:00AM EDT  Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, today announced that Steven Nichtberger, M.D., President and Chief Executive Officer, will present at the following three upcoming investor conferences in October:   GlobeNewswire Inc
Sep 8, 2020
08:00AM EDT  Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, today announced its participation in fireside chats at the following upcoming September investor conferences:   GlobeNewswire Inc
Aug 25, 2020
08:07AM EDT  Cabaletta Bio Highlights Publication Of Comprehensive Preclinical Study Results For DSG3-CAART In Pemphigus Vulgaris   Benzinga
08:00AM EDT  -- DSG3-CAART achieved autoantibody elimination and resolution of blisters in active immune mouse model of pemphigus vulgaris -- Soluble autoantibodies demonstrated potential to enhance DSG3-CAART efficacy and did not demonstrate off-target toxicity -- DesCAARTes Phase 1 clinical trial actively recruiting patients   GlobeNewswire Inc
Aug 6, 2020
10:36AM EDT  Cabaletta Bio Earlier Reported Q2 EPS $(0.35) Up From $(1.87) YoY   Benzinga
07:30AM EDT  Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, today announced financial results for the second quarter ended June 30, 2020 and provided a business update.   GlobeNewswire Inc
Jul 15, 2020
10:05AM EDT  Morgan Stanley Maintains Overweight on Cabaletta Bio, Raises Price Target to $20   Benzinga


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2026 ChartExchange LLC